Cargando…

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden

This case-control study examines the risk of severe COVID-19 infection in individuals with multiple sclerosis who were receiving rituximab.

Detalles Bibliográficos
Autores principales:	McKay, Kyla A., Piehl, Fredrik, Englund, Simon, He, Anna, Langer-Gould, Annette, Hillert, Jan, Frisell, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637249/ https://www.ncbi.nlm.nih.gov/pubmed/34851401 http://dx.doi.org/10.1001/jamanetworkopen.2021.36697

Ejemplares similares

Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
por: Razaz, Neda, et al.
Publicado: (2020)

Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
por: Fink, Katharina, et al.
Publicado: (2023)

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations
por: Alping, Peter, et al.
Publicado: (2019)

Rituximab, MS, and pregnancy
por: Smith, Jessica B., et al.
Publicado: (2020)

COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls
por: Longinetti, Elisa, et al.
Publicado: (2022)

Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
por: Starvaggi Cucuzza, Chiara, et al.
Publicado: (2022)

Risk of depression in multiple sclerosis across disease-modifying therapies
por: Longinetti, Elisa, et al.
Publicado: (2021)

Multiple sclerosis, rituximab, and COVID‐19
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study
por: Binzer, Stefanie, et al.
Publicado: (2019)

Multiple Sclerosis, Disease-Modifying Therapies, and Infections
por: Langer-Gould, Annette M., et al.
Publicado: (2023)

Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
por: Piehl, Fredrik, et al.
Publicado: (2022)

Long-term disability progression of pediatric-onset multiple sclerosis
por: McKay, Kyla A., et al.
Publicado: (2019)

Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis
por: Smith, Jessica B., et al.
Publicado: (2022)

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
por: Alping, Peter, et al.
Publicado: (2021)

A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis
por: Evertsson, Björn, et al.
Publicado: (2020)

Association between brain volume and disability over time in multiple sclerosis
por: Moridi, Thomas, et al.
Publicado: (2022)

Determinants of quality of life in pediatric- and adult-onset multiple sclerosis
por: McKay, Kyla A., et al.
Publicado: (2020)

Cerebrospinal fluid markers in incident pediatric-onset multiple sclerosis: a nationwide study
por: McKay, Kyla A., et al.
Publicado: (2021)

Acute Myocardial Infarction after First Dose of Rituximab Infusion
por: Gogia, Ajay, et al.
Publicado: (2014)

Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study
por: He, Anna, et al.
Publicado: (2023)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
por: Salzer, Jonatan, et al.
Publicado: (2016)

Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse
por: McKay, Kyla A., et al.
Publicado: (2022)

Premorbid Sociodemographic Status and Multiple Sclerosis Outcomes in a Universal Health Care Context
por: He, Anna, et al.
Publicado: (2023)

Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar
por: Courville, Jocelyn, et al.
Publicado: (2021)

Non-infectious comorbidity in patients with multiple sclerosis: A national cohort study in Sweden
por: Castelo-Branco, Anna, et al.
Publicado: (2020)

Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis
por: He, Anna H, et al.
Publicado: (2023)

Familial risk of early- and late-onset multiple sclerosis: a Swedish nationwide study
por: Song, Jie, et al.
Publicado: (2018)

Administrative data for observational research in multiple sclerosis: Opportunities and challenges
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Impact of Split Dosing the First Rituximab Infusion in Patients with High Lymphocyte Count
por: Plante, Maude, et al.
Publicado: (2021)

A multiple sclerosis disease progression measure based on cumulative disability
por: Manouchehrinia, Ali, et al.
Publicado: (2021)

SEVERE ADENOVIRUS PNEUMONIA IN RITUXIMAB INFUSIONS
por: BJORK, SARAH, et al.
Publicado: (2021)

COVID-19 outcomes in persons with multiple sclerosis treated with rituximab
por: Iyer, Rajesh B, et al.
Publicado: (2022)

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
por: Boremalm, Malin, et al.
Publicado: (2021)

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial
por: Piehl, Fredrik, et al.
Publicado: (2022)

Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study
por: Smith, Kelsi A, et al.
Publicado: (2023)

Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
por: Patel, Jolly, et al.
Publicado: (2013)

Allergic/infusion reactions reported with cetuximab and rituximab
por: Wolf, Ray A, et al.
Publicado: (2015)

New data identify an increasing sex ratio of multiple sclerosis in Sweden
por: Westerlind, Helga, et al.
Publicado: (2014)

The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience
por: Nissen, Johanna C, et al.
Publicado: (2014)

Hospital-treated infections in early- and mid-life and risk of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis: A nationwide nested case-control study in Sweden
por: Sun, Jiangwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_se4l6te1vcvd52b9k35ch48f5k